PL371675A1 - Sposób odwzorowywania oraz eliminowania epitopów limfocytu T - Google Patents

Sposób odwzorowywania oraz eliminowania epitopów limfocytu T

Info

Publication number
PL371675A1
PL371675A1 PL03371675A PL37167503A PL371675A1 PL 371675 A1 PL371675 A1 PL 371675A1 PL 03371675 A PL03371675 A PL 03371675A PL 37167503 A PL37167503 A PL 37167503A PL 371675 A1 PL371675 A1 PL 371675A1
Authority
PL
Poland
Prior art keywords
epitopes
identification
mapping
eliminating
cell epitopes
Prior art date
Application number
PL03371675A
Other languages
English (en)
Inventor
Matthew Baker
Francis J. Carr
Graham Carter
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL371675(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL371675A1 publication Critical patent/PL371675A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL03371675A 2002-06-11 2003-06-11 Sposób odwzorowywania oraz eliminowania epitopów limfocytu T PL371675A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02012919 2002-06-11

Publications (1)

Publication Number Publication Date
PL371675A1 true PL371675A1 (pl) 2005-06-27

Family

ID=29724386

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03371675A PL371675A1 (pl) 2002-06-11 2003-06-11 Sposób odwzorowywania oraz eliminowania epitopów limfocytu T

Country Status (16)

Country Link
EP (1) EP1512004B1 (pl)
JP (1) JP2005529170A (pl)
CN (1) CN100401064C (pl)
AT (1) ATE320603T1 (pl)
AU (1) AU2003273679A1 (pl)
BR (1) BR0311720A (pl)
CA (1) CA2489180A1 (pl)
DE (1) DE60304040T2 (pl)
DK (1) DK1512004T3 (pl)
ES (1) ES2257680T3 (pl)
MX (1) MXPA04012209A (pl)
PL (1) PL371675A1 (pl)
PT (1) PT1512004E (pl)
RU (1) RU2334235C2 (pl)
WO (1) WO2003104803A2 (pl)
ZA (1) ZA200500214B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004213565A1 (en) * 2003-02-18 2004-09-02 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
CA2560278C (en) 2004-03-19 2012-11-20 Matthew Baker Modified bouganin proteins, cytotoxins and methods and uses thereof
FR2940451B1 (fr) 2008-12-18 2014-09-12 Proteus Procede d'evaluation de l'immunogenicite des proteines
GB201917630D0 (en) * 2019-12-03 2020-01-15 Ge Healthcare Bio Sciences Ab Method for determination of aggregates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5945401A (en) * 1995-06-23 1999-08-31 Conlon; Paul J. Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
GB2349463B (en) * 1996-03-21 2001-01-10 Circassia Ltd Cryptic peptides and method for their identification
US5750356A (en) * 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
CA2424720C (en) * 2000-10-02 2012-04-03 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same

Also Published As

Publication number Publication date
DK1512004T3 (da) 2006-06-06
ATE320603T1 (de) 2006-04-15
RU2005100758A (ru) 2006-01-20
WO2003104803A2 (en) 2003-12-18
BR0311720A (pt) 2005-03-01
DE60304040D1 (de) 2006-05-11
WO2003104803A3 (en) 2004-04-15
JP2005529170A (ja) 2005-09-29
ES2257680T3 (es) 2006-08-01
AU2003273679A1 (en) 2003-12-22
CN100401064C (zh) 2008-07-09
RU2334235C2 (ru) 2008-09-20
EP1512004B1 (en) 2006-03-15
CN1659437A (zh) 2005-08-24
DE60304040T2 (de) 2006-09-28
ZA200500214B (en) 2006-02-22
EP1512004A2 (en) 2005-03-09
CA2489180A1 (en) 2003-12-18
PT1512004E (pt) 2006-08-31
MXPA04012209A (es) 2005-02-25

Similar Documents

Publication Publication Date Title
DE60142689D1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
TW200510459A (en) RG1 antibodies and uses thereof
WO2004091543A3 (en) Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
SI1644484T1 (sl) Avtologne samo-toleranco inducirajoče celice monocitnega izvora in njihova uporaba v farmacevtskihpripravah
PL1699822T3 (pl) Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie
DK1620456T3 (da) Hla-a2 tumor-associerede antigen-peptider og præparater
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
WO2003068941A3 (en) Modulation of immune response by non-peptide binding stress response polypeptides
ATE319745T1 (de) Verfahren zur herstellung von nicht-immunogenen proteinen
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
ATE356206T1 (de) Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
BRPI0513135A (pt) bibliotecas de polinucleotìdeos, método de produção das mesmas, método de identificação de um polinucleotìdeo, região de ligação, meio adequado para uso em um, dispositivo eletrÈnico e dispositivo
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
MY141459A (en) Recombinant anti-idiotypic antibodies
ZA200500214B (en) Method for mapping and eliminating T-cell epitopes.
AU2174002A (en) Method for analyzing proteins
ATE316577T1 (de) Das goodpasture-antigen bindende protein
NO20005952L (no) Antigene polypeptider fra Neisseria Meningitidis, tilsvarende polynukleotider og beskyttende antistoffer
AU2003241127A1 (en) MEMBRANE-ANCHORED Beta2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES
DE602006010934D1 (de) Verfahren zur Identifizierung von Epitopen in Zusammenhang mit Immunogenität bei Biopharmazeutika
Knopf et al. Novel function of complement C3d as an autologous helper T‐cell target
MY144766A (en) Plant virus coat fusion proteins with gdf8 epitopes and vaccines thereof
GB2416694A (en) Methods for recombinant immunoglobulin treatment

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)